meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA)
1
mEC - 1st line (L1)
1
mEC - 2nd line (L2)
3
gastric or gastroesophageal junction cancer (GC)
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">nivolumab based treatment</span>
<span style="margin-left: 3em;">nivolumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">non active control</span>
<span style="margin-left: 1em;">placebo <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
events or deaths (EFS) (1)
TRAE (any grade) (2)
TRAE (grade 3-4) (2)
AE (any grade) (1)
SAE (any grade) (1)
AE leading to treatment discontinuation (any grade) (1)
AE leading to treatment discontinuation (grade 3-4) (1)
AE (grade 3-4) (1)
SAE (grade 3-4) (1)
STRAE (any grade) (1)
STRAE (grade 3-4) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for EEEE
placebo
nivolumab alone
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
placebo
nivolumab alone
placebo
---
NA
nivolumab alone
NA
---
pathologies: 151 - treatments: 360,719,721,720
result logic
×
Study list